Please assess the completion status of the following clinical trial:

Trial Title: A 28 Day Parallel Group Study to Assess the Effects of RDN-929

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males or postmenopausal or surgically sterile females age 55 - 85 years old.~* Healthy as determined by the Investigator, based on a medical evaluation including medical history, physical examination, neurological examination, laboratory tests and ECG recording~Exclusion Criteria:~* Any history of major psychiatric disorders, including substance use disorders, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal (ULN)~* A clinically significant abnormality on physical examination, neurological examination, ECG, or laboratory evaluations~* A clinically significant vital signs abnormality, as judged by the principal investigator

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- RDN-929 (Type: EXPERIMENTAL): low, medium and high dose of RDN-929 capsules
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).